undamentalytics Newsletter
Sign in

Sinovac Biotech LTD income statement

In fiscal 2025, Sinovac Biotech LTD reported revenue of $386m, up 6.8% on the year before, operating income of −$490m (a -127.0% margin) and net income of −$59.7m, or −$0.83 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue0.10.00.10.10.20.20.20.519.41.50.50.40.4
Cost of revenue0.00.00.00.00.00.00.00.11.00.70.10.10.1
Gross profit0.10.00.00.10.20.20.20.418.40.80.30.20.3
Research and development0.00.00.00.00.00.00.00.00.20.50.40.30.2
Selling, general and administrative0.00.00.00.00.10.10.10.20.60.80.60.40.3
Operating income0.0−0.00.00.00.00.00.10.217.6−0.5−0.7−0.5−0.5
Income before tax0.0−0.00.0−0.00.00.00.10.217.6−0.0−0.10.0−0.3
Income tax0.0−0.00.00.00.00.00.00.03.40.00.00.0−0.1
Net income0.0−0.0−0.0−0.00.00.00.00.18.10.0−0.00.1−0.1
Diluted EPS$0.46−$0.16−$0.02−$0.01$0.45$0.34$0.41$0.97$113.44$0.20−$0.19$1.27−$0.83
Diluted shares (average)43m53m55m57m57m65m110m114m72m72m72m72m72m
EBITDA0.0−0.00.00.00.10.10.10.217.7−0.4−0.6−0.4−0.4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MNKD vs SVAPHAR vs SVAMGTX vs SVANVAX vs SVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sinovac Biotech LTD's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Sinovac Biotech LTD.